Compare Global X Lithium & Battery Tech ETF (LIT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.07, while State Street SPDR S&P Biotech ETF trades at $154.41. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals.
| LIT | XBI | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $91.62 | $164.28 |
52-Week Low | $40.80 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT trades at $66.92, down 2.14% with a bearish technical signal from moving averages despite oversold RSI readings. The ETF focuses on lithium and battery technology, benefiting from global EV sales growth and China's 30% NEV fleet target by 2030. Recent news highlights momentum in energy storage and semiconductors, though key financial ratios are unavailable.
Outlook is mixed: bullish catalysts from EV adoption and AI demand support long-term growth, but near-term risks include regulatory pressures, Chinese market access tensions, and reliance on lithium price stability. Investor sentiment is cautious amid technical weakness and geopolitical factors affecting auto industry dynamics.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
